Avalo Therapeutics Inc
AVTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$963M
Close$
$0.99
94.9% downside
Current Fair Value
94.9% downsideOvervalued by 94.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $963.00 Million |
|---|---|
| Enterprise Value | $877.62 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.84 |
| Beta | 0.79 |
| Outstanding Shares | 43,602,044 |
Return
| Return on Equity | -22.36% |
|---|---|
| Return on Assets | -20.44% |
| Return on Invested Capital | -20.48% |
Valuation & Multiples
| P/E Ratio | -3.86 |
|---|---|
| PEG | -5.15 |
| Price to Sales | - |
| Price to Book Ratio | 1.95 |
| Enterprise Value to Revenue | 14874.91 |
| Enterprise Value to EBIT | -9.12 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.63
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1301▼ 45.51% |
|---|---|
| Total Calls | 2,813,100▲ 792.76% |
| Total Puts | 365,900▲ 98.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 232.04%▲ 83.69% |
|---|---|
| Total Invested | $464.19M▲ 28.54% |
| Investors Holding | 109▲ 16.00% |
ESG Score
No data
About Avalo Therapeutics Inc
31 employeesCerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that ad...